Objective: The purpose of this study was to evaluate the comparative efficacy and safety of a
novel long-duration multilayer-release (MLR) methylphenidate (MPH) formulation and …

Objective. A new once-a-day methylphenidate (MPH) formulation, Concerta
(methylphenidate HCl) extended-release tablets (OROS MPH), has been developed. This …

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common behavioral
disorders in childhood. It continues into adulthood in up to 65% of patients. Methylphenidate …

Objectives: To assess the efficacy and safety of a methylphenidate hydrochloride extended-
release capsule (MPH-MLR) formulation in treating attention-deficit/hyperactivity disorder …

Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioural disorder with
onset during childhood. It affects a child's development, both at home and at school, and …

Objective: The purpose of this study was to assess the time of onset and time course of
efficacy over 12.0 hours of extended-release multilayer bead formulation of methylphenidate …

Objective: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODTs)
represent a new technology for MPH delivery. ODTs disintegrate in the mouth without water …

Objectives. To evaluate the safety and efficacy of osmotic-controlled release oral delivery
system (OROS) methylphenidate (MPH) HCl in adults with attention-deficit/hyperactivity …

Background The thrice daily dosing regimen of immediate release methylphenidate (IR-
MPH) for Attention Deficit/Hyperactivity Disorder (ADHD) requires in-school dosing, leading …

Objective: The purpose of this study was to determine the efficacy of NWP06, a novel
extended-release (ER) liquid formulation of methylphenidate (MPH), compared with placebo …